{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:28:35Z","timestamp":1791347315818,"version":"4.3.1"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,4]]},"DOI":"10.1097\/qai.0b013e31819c33a3","type":"journal-article","created":{"date-parts":[[2009,5,21]],"date-time":"2009-05-21T08:43:18Z","timestamp":1242895398000},"page":"439-443","source":"Crossref","is-referenced-by-count":59,"title":["Effect of Rifampicin on Efavirenz Pharmacokinetics in HIV-Infected Children With Tuberculosis"],"prefix":"10.1097","volume":"50","author":[{"given":"Yuan","family":"Ren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James J C","family":"Nuttall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian S","family":"Eley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tammy M","family":"Meyers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen M","family":"McIlleron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-1-20210131","doi-asserted-by":"crossref","first-page":"681","DOI":"10.2165\/00003088-200241090-00004","article-title":"Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis.","volume":"41","author":"Lopez-Cortes","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R4-1-20210131","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/QAI.0b013e31805c9d52","article-title":"High prevalence of subtherapeutic plasma levels of efavirenz in children.","volume":"45","author":"Ren","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R6-1-20210131","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0731-7085(02)00357-6","article-title":"Simultaneous determination of five HIV protease inhibitors nelfinavir, indinavir, ritonavir, saquinavir and amprenavir in human plasma by LC\/MS\/MS.","volume":"30","author":"Chi","year":"2002","journal-title":"J Pharm Biomed Anal"},{"key":"R7-1-20210131","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1177\/135965350501000114","article-title":"Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.","volume":"10","author":"Kappelhoff","year":"2005","journal-title":"Antivir Ther"},{"key":"R8-1-20210131","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/jac\/dkl399","article-title":"Administration of efavirenz (600 mg\/day) with rifampicin results in high variable levels but excellent clinical outcomes in patients treated for tuberculosis and HIV.","volume":"58","author":"Friedland","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"R10-1-20210131","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1177\/135965350801300507","article-title":"Factors influencing efavirenz and nevirapine plasma concentration: effect of ethnicity, weight and co-medication.","volume":"13","author":"Stohr","year":"2008","journal-title":"Antivir Ther"},{"key":"R11-1-20210131","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1007\/s00228-001-0396-3","article-title":"Isoniazid is a mechanism-based inhibitor of cytochrome P450 1A2, 2A6, 2C19 and 3A4 isoforms in human liver microsomes.","volume":"57","author":"Wen","year":"2002","journal-title":"Eur J Clin Pharmacol"},{"key":"R13-1-20210131","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/00002030-200101050-00011","article-title":"Efavirenz levels can predict treatment failure and central nervous system side effects in HIV-1 infected patients.","volume":"15","author":"Marzolini","year":"2001","journal-title":"AIDS"},{"key":"R14-1-20210131","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1097\/00002030-200410210-00017","article-title":"Higher efavirenz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations.","volume":"18","author":"Gonzalez de Requena","year":"2004","journal-title":"AIDS"},{"key":"R15-1-20210131","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2165\/00003088-200241140-00001","article-title":"Antiretroviral pharmacokinetics in the paediatric population.","volume":"41","author":"King","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"R16-1-20210131","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/QAI.0b013e318040b29e","article-title":"Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.","volume":"45","author":"Saitoh","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R17-1-20210131","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1093\/jac\/dkn112","article-title":"Antiviral efficacy, tolerability and pharmacokinetics of efavirenz in an unselected cohort of HIV-infected children.","volume":"61","author":"Wintergerst","year":"2008","journal-title":"J Antimicrob Chemother"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00126334-200904150-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:46:10Z","timestamp":1786038370000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00126334-200904150-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0b013e31819c33a3","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}